Compare EXP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | RYTM |
|---|---|---|
| Founded | 1963 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.8B |
| IPO Year | 1994 | 2017 |
| Metric | EXP | RYTM |
|---|---|---|
| Price | $214.29 | $115.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $227.11 | $131.14 |
| AVG Volume (30 Days) | 460.6K | ★ 640.7K |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 3.29 | N/A |
| Revenue | ★ $495,023,000.00 | N/A |
| Revenue This Year | $1.97 | $55.34 |
| Revenue Next Year | $1.95 | $86.06 |
| P/E Ratio | $64.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $171.99 | $74.50 |
| 52 Week High | $245.53 | $122.20 |
| Indicator | EXP | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 60.52 |
| Support Level | $202.41 | $98.76 |
| Resistance Level | $223.21 | $113.03 |
| Average True Range (ATR) | 7.94 | 4.84 |
| MACD | 0.79 | 0.15 |
| Stochastic Oscillator | 49.42 | 98.64 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.